JAK2 and myeloproliferative neoplasm: A similar trend was observed for MPL-positive and triple negative MPN patients (lacking JAK2, MPL, and CALR mutations), however, statistical significance is absent, possibly due to low sample sizes (Supporting Information Table 1).